What's Happening?
Silexion Therapeutics has announced the initiation of Good Manufacturing Practice (GMP) clinical batch manufacturing for its RNA interference therapy, SIL204, targeting KRAS-driven pancreatic cancer. This development is in preparation for a Phase 2/3
clinical trial in locally advanced pancreatic cancer. The manufacturing is being conducted in collaboration with Catalent at its European center of excellence. The trial has received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center, marking a significant milestone in the clinical site activation process. The drug product is being manufactured to support the safety run-in segment of the trial, with the active pharmaceutical ingredient having been successfully produced in 2025.
Why It's Important?
The initiation of GMP manufacturing for SIL204 is a critical step in advancing Silexion's clinical trial efforts for treating KRAS-driven pancreatic cancer, a condition with limited treatment options. The collaboration with Catalent, a leader in complex injectable formulations, enhances the drug's stability and delivery precision. This progress underscores Silexion's commitment to developing innovative cancer therapies and reflects regulatory momentum in Israel and Germany. The trial's success could potentially lead to new treatment paradigms for pancreatic cancer, benefiting patients with this aggressive disease.
What's Next?
Silexion is preparing for the first patient dosing in the Phase 2/3 trial, with ongoing regulatory reviews in Germany. The company is focused on ensuring Chemistry, Manufacturing, and Controls (CMC) readiness and advancing operational steps to bring SIL204 into human trials. The collaboration with Catalent will continue to optimize the drug's delivery formulations, supporting Silexion's dual-route administration strategy. The trial will evaluate SIL204 in combination with standard chemotherapy, aiming to improve treatment outcomes for patients with locally advanced pancreatic cancer.
